HSCEI Index Earning Revision (May): Xiaomi, ICBC, China Life, CCB, Meituan, Smic, Beigene
We analyzed HSCEI's consensus for May 2025 and highlighted changes of EPS in Xiaomi - W, ICBC, China Life, CCB, Meituan - W, Smic, Beigene.
6.2k Views
Pre-IPO GenFleet Therapeutics - The Pipeline Outlook Is Full of Challenges
KRAS field hits druggability milestone but struggles with efficacy in NSCLC/CRC.GFH925 must show strong efficacy/safety for commercial...
522 Views
A-H Premium Weekly (May 23rd): CATL and Hengrui Listing Lowered Premium
We analyzed A-H premium changes in the past week and highlight A-H premium changes for Asymchem Lab, Shanghai Junshi Biosciences, Remegen, Fuyao...
421 Views
China Healthcare Weekly (May.18) - Trump to Lower US Drug Prices, Thoughts on Hengrui's IPO Pricing
Hengrui's HK IPO debut is strong, driven by positive sentiment for AH listing and the small IPO size (225 million circulating shares). Investors...
720 Views
Jiangsu Hengrui Pharma A/H Trading - Strong Demand for Quality Asset, but Is Pricey
Jiangsu Hengrui Pharmaceuticals (1276 HK) (JHP, 600276 CH ), a China-based pharmaceutical company, raised around US$1.5bn in its H-share listing....
417 Views